Gadicke Ansbert
CIK 0001134655
Director10% Owner
Filings
19
Latest Jan 14, 2026
Issuers covered
7
Showing
19 of 19
Page 1
Track record
32 of 39 open-market trades scored (82% price coverage) - 7 issuers without price data. Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 32 | 84% | +20.7% | +26.1% | +42.2% | -17.0% |
| 90 days | 32 | 94% | +35.5% | +36.6% | +61.6% | -20.3% |
| 180 days | 31 | 97% | +43.7% | +47.1% | +60.5% | -67.3% |
| 365 days | 3 | 100% | +40.4% | +45.7% | +48.4% | +27.0% |
Issuers
Companies where Gadicke Ansbert has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| HOWL | Werewolf Therapeutics, Inc. | 10 | Dec 4, 2025 |
| CGEM | Cullinan Oncology, Inc. | 2 | Jun 23, 2022 |
| TCRR | Tcr2 Therapeutics Inc. | 2 | Jun 5, 2023 |
| ITOS | Iteos Therapeutics, Inc. | 2 | May 15, 2025 |
| AKTS | Aktis Oncology, Inc. | 1 | Jan 14, 2026 |
| ALVR | Allovir, Inc. | 1 | May 19, 2022 |
| TRDA | Entrada Therapeutics, Inc. | 1 | Dec 12, 2024 |
All filings
19 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|